¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"half survival time"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® half-life ÇÑ±Û ¹Ý°¨±â
¼³¸í   
  ¾î¶² ¹°ÁúÀÌ ¿ÜºÎÀû ¿äÀÎ, ¶Ç´Â ³»ºÎÀû ¿äÀο¡ ÀÇÇØ¼­ ºÐÇØµÉ °æ¿ì¿¡ ±× ¹°ÁúÀÇ ¿ø·¡ÀÇ ¾ç¿¡¼­ ¹ÝÀÌ µÇ´Â µ¥ °É¸®´Â ½Ã°£.
¿µ¹® five-year survival rate ÇÑ±Û ¿À³â»ýÁ¸À²
¼³¸í   
  1. µ¿ÀÏ Áúº´ÀÇ Áø´Ü È¤Àº Ä¡·á ÈÄ, 5³âÀÌ °æ°ú µÈ µÚÀÇ »ýÁ¸ÀÚ¼öÀǠǥÇö. 2. ¾ÏÀÇ Áø´Ü ¶Ç´Â Ä¡·á µÚ¿¡ °Ë»ç¸¦ ¹Ýº¹ÇÏ¿© 5³â µ¿¾È »ì¾Æ Àִ »ç¶÷ÀÇ ¹éºÐÀ². Ä¡·á ÈÄ 5³â µ¿¾È »ýÁ¸Çϸé ÀÏ´Ü Ä¡À¯µÈ °ÍÀ¸·Î °£ÁÖÇÑ´Ù.
¿µ¹® coagulation time ÇÑ±Û ÀÀ°í½Ã°£
¼³¸í   
  Ç÷¾×ÀÀ°í¶õ ÁöÇ÷ÀÇ ÇÑ °úÁ¤À¸·Î ¼¶À¯¼Ò¶õ ¹°ÁúÀ» ¸¸µé¾î ³»´Â °úÁ¤ÀÌ´Ù. ÀÌ ¼¶À¯¼Ò¶õ ¹°ÁúÀº ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¿¡ ÀÛ¿ëÇÏ¿© ¿©·¯ °¡Áö ¼¼Æ÷µéÀ» ¾ô¾î ¹­´Â ¿ªÇÒÀ» ÇÏ¿© °á±¹ ¼Õ»óµÈ Ç÷°ü¿¡¼­ Ç÷¾×ÀÇ ¼Ò½ÇÀ» ¸·´Â´Ù. Ç÷¾×ÀÀ°í´Â ´ÙÀ½°ú °°Àº 3´Ü°è·Î ÀÌ·ç¾îÁø´Ù.
  
  Ã¹¹øÂ° ´Ü°è´Â Ç÷°ü¼Õ»ó¿¡ ÀÇÇØ¼­ prothrombin activator¶ó´Â °ÍÀÌ ¸¸µé¾îÁö´Â ´Ü°èÀÌ´Ù. µÎ¹øÂ° ´Ü°è´Â ÀÌ prothrombin activator¶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ Ç÷¾×¼Ó¿¡ Àִ ÇÁ·ÎÆ®·ÒºóÀ̶ó´Â ¹°ÁúÀÌ Æ®·ÒºóÀ̶ó´Â ¹°Áú·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù. ¼¼¹øÂ° ´Ü°è´Â Æ®·ÒºóÀ̶ó´Â ¹°Áú¿¡ ÀÇÇØ¼­ ¼¶À¯¼Ò¿øÀ̶ó´Â ¹°ÁúÀÌ ¼¶À¯¼ÒÀ¸·Î ¹Ù²î´Â ´Ü°èÀÌ´Ù.
  
  ÀÀ°íÀÛ¿ëÀº Å©°Ô 2°¡Áö·Î ³ª´µ´Âµ¥, ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀÚ°¡ ±×°ÍÀÌ´Ù. ¿ÜÀμº ÀÀ°íÀÎÀÚ¿Í ³»Àμº ÀÀ°íÀÎÀڴ °¢±â º°°³·Î ÀÛ¿ëÇÏÁö¸¸, °á±¹Àº ¸¶Áö¸· °úÁ¤¿¡¼­ Çϳª·Î ¸¸³ª¼­ ¼¶À¯¼Ò¿øÀ» ¼¶À¯¼Ò(ÀÀ°íÀÛ¿ëÀÇ ¸¶Áö¸· ´Ü°è¿¡ »ý¼ºµÇ¸ç ´Ü´ÜÇϰí Ç®¸®Áö ¾Ê´Â ¸ÅµìÀ» Çü¼ºÇÏ¿© ÁöÇ÷ÀÛ¿ëÀ» ¿Ï¼ºÇÑ´Ù)À¸·Î ¸¸µé¾î ÀÀ°íÀÛ¿ëÀ» ³ªÅ¸³½´Ù.
¿µ¹® bleeding time ÇÑ±Û ÃâÇ÷½Ã°£
¼³¸í   
  ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖ¾úÀ» °æ¿ì¿¡ Çǰ¡ ¸Ü´Âµ¥ ±îÁö °É¸®´Â ½Ã°£À» ÃâÇ÷½Ã°£À̶ó°í ÇÑ´Ù. »ç¶÷ÀÇ ¸ö¿¡ »óó°¡ ³ª¼­ ÃâÇ÷ÀÌ ÀÖÀ» °æ¿ì¿¡ À̰ÍÀ» ¸·°í ÇǸ¦ ´õÀ̻󠳪Áö ¾Ê°Ô Çϴ °ÍÀ» ÁöÇ÷À̶ó°í ÇÑ´Ù. ÁöÇ÷ÀÇ °úÁ¤¿¡´Â Å©°Ô µÎ °¡Áö ´Ü°è°¡ ÀÖ´Ù. Ã¹¹øÂ° ´Ü°è´Â Ç÷¼ÒÆÇµéÀÌ »óó°¡ ³ª¼­ ¼Õ»óµÈ Ç÷°üÀÇ ºÎÀ§¸¦ ¸·´Â °ÍÀÌ´Ù. ÀÌ·¸°Ô Çϸ頿켱 Ç÷°üÀÇ ¼Õ»óºÎÀ§·ÎºÎÅÍ Çǰ¡ ³ª¿À´Â °ÍÀ» ¸·À» ¼ö°¡ ÀÖ´Ù. ´ÙÀ½ÀÇ ´Ü°è´Â »ó󸦠¸·°í Àִ Ç÷¼ÒÆÇÀ§¿¡ ¿©·¯ °¡Áö ¹°ÁúµéÀÌ ÀÛ¿ëÇØ¼­ ´õ¿í ´Ü´ÜÇϰԠÇÏ¿© »óó°¡ ³­ Ç÷°ü¿¡¼­ Çǰ¡ »õ´Â °ÍÀ» ¿µ±¸È÷ ¸·´Â °ÍÀÌ´Ù. ½±°Ô ¸»Çϸé Ç÷¼ÒÆÇÀº º®µ¹¿¡ ÇØ´çÇϴ °ÍÀÌ°í µÎ¹øÂ° °úÁ¤¿¡ Âü¿©Çϴ ¹°ÁúµéÀº ½Ã¸àÆ®¿¡ ÇØ´çÇϴ °ÍÀÌ´Ù. ÀÌ µÎ °úÁ¤ÀÌ ¿ÏÀüÇÒ °æ¿ì¿¡ ÁöÇ÷ÀÌ ¼øÁ¶·Ó°Ô ÀϾ´Ù.
  
  ÃâÇ÷½Ã°£Àº À§¿¡¼­ ¼³¸íÇÑ ÁöÇ÷ÀÇ µÎ°¡Áö °úÁ¤ Áß¿¡¼­ Ã¹¹øÂ° °úÁ¤¿¡ ÀÇÇØ¼­¸¸ ¿µÇâÀ» ¹Þ´Â´Ù. Áï ¼Õ»óµÈ Ç÷°üÀ» ¸·¾ÆÁִ º®µ¹¿¡ ÇØ´çÇϴ Ç÷¼ÒÆÇÀÇ ±â´É¸¸ Á¤»óÀÏ °æ¿ì¿¡ ÃâÇ÷½Ã°£Àº Á¤»óÀ¸·Î ³ª¿Â´Ù. ¸¸¾à Ç÷¼ÒÆÇÀÇ ±â´É¿¡ ÀÌ»óÀÌ Àִ °æ¿ì¿¡´Â ÀÚ¿¬È÷ ÃâÇ÷½Ã°£ÀÌ ±æ¾îÁø´Ù.
¿µ¹® prothrombin time ÇÑ±Û ÇÁ·ÎÆ®·Òºó½Ã°£
¼³¸í   
  ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼­ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î Æ¯Á¤Çϴ °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half and half nail
    ¹Ý°ú¹Ý¼Õ¹ßÅé
  • survival time
    »ýÁ¸±â°£
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • biologic half-life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • half bath
    ¹Ý½Å¸ñ¿å, ¹Ý½Å¿å
  • half elimination rate
    ¹Ý°¨·ü
  • half shell crown
    ¹Ý±Ý°ü
  • half-axial projection
    ¹ÝÃ༺Åõ»ç
  • half-life
    ¹Ý°¨±â
  • half-normal saline
    1/2»ý¸®½Ä¿°¼ö
  • half-normal solution
    ¹Ý±ÔÁ¤¾×
  • half-value layer
    ¹Ý°¡Ãþ
  • crude survival rate
    º¸Åë»ýÁ¸À², Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival time
    »ýÁ¸±â°£
  • half-life
    ¹Ý°¨±â
  • survival analysis
    »ýÁ¸ºÐ¼®
  • selective survival bias
    ¼±ÅûýÁ¸Ä¡¿ìħ, ¼±ÅûýÁ¸¿ÀÂ÷
  • survival curve
    »ýÁ¸°î¼±
  • five-year survival rate
    ¿À³â»ýÁ¸·ü
  • survival rate
    »ýÁ¸·ü
  • survival
    »ýÁ¸
  • time
    ½Ã°£
  • acquisition time
    ȹµæ½Ã°£
  • activated partial thromboplastin time
    Ȱ¼ºÈ­ºÎºÐÆ®·Òº¸ÇÃ¶ó½ºÆ¾½Ã°£
  • bleeding time
    ÃâÇ÷½Ã°£
  • clot retraction time
    ÇǶ±µÞ´ç±è½Ã°£, Ç÷º´ÅðÃà½Ã°£
  • coagulation time
    ÀÀ°í½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half survival time
    ¹Ý°¨»ýÁ¸½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival time
    »ýÁ¸±â°£
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • half bath
    ¹Ý½Å¸ñ¿å
  • half shell crown
    ¹Ý±Ý°ü
  • elimination half-life
    ¼Ò½Ç¹Ý°¨±â
  • half-life
    ¹Ý°¨±â
  • half tone
    ¹ÝÀ½
  • half elimination rate
    ¹Ý°¨·ü
  • half waking somnambulism
    ¹Ý°¢¼º¸ùÀ¯º´
  • half-normal solution
    ¹Ý±ÔÁ¤¾×
  • half-value layer
    ¹Ý°¡Ãþ
  • physical half life
    ¹°¸®Àû¹Ý°¨±â
  • survival analysis
    »ýÁ¸ºÐ¼®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half and half nail
    ¹Ý¹Ý Á¶°©
  • half time for saturation
    ¹ÝÆ÷È­±â(ÚâøéûúÑ¢).
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • platelet survival measurement
    Ç÷¼ÒÆÇ»ýÁ¸´ÉÃøÁ¤
  • probability of survival
    »ýÁ¸(È®)·ü(Ë×Ì¡ Ì·Ëô).
  • red blood cell survival test
    ÀûÇ÷±¸¼ö¸í½ÃÇè(îåúìϹáøÙ¤ãËúÐ).
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • antibody half-life
    Ç×ü¹Ý°¨±â(ù÷ô÷ÚâÊïÑ¢).
  • half Fourier imaging
    ¹Ý Fourier ¿µ»ó
  • half bath
    ¹Ý½Å¿å(Úâãóé±).
  • half elimination rate
    1/2Á¦°ÅÀ²(ð¶ËÛëÒ), ¹Ý°¨·ü(ÚâÊõ×Ë)
  • half elimination rate
    1/2Á¦°ÅÀ², ¹Ý°¨·ü.
  • half fat cheese
    ¹ÝÅ»ÁöÄ¡ÀÌÁî.
  • half lethal dose
    ¹ÝÄ¡»ç·®(ÚâöÈÞÝåÖ).
  • half normal solution
    0.5 ±ÔÁ¤¾×(¡­Ð®ïÒäû).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ËÑ˧ ËÛËÎ).
  • half survival time
    ¹Ý°¨ÀÜ»ý¼ö¸í(ÚâÊõíÑßæáøÙ¤).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half and half nail
    ¹Ý¹Ý Á¶°©
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£(̰˻Ë×Ì¡Ëà˧).
  • survival time
    »ýÁ¸±â°£(ÊÙ˻˧).
  • survival time
    »ýÁ¸±â°£(ßæðíÑ¢Êà)
  • half time for saturation
    ¹ÝÆ÷È­±â(ÚâøéûúÑ¢).
  • arctic survival
    ±ØÇÑ»ýÁ¸(пùÎßæðí).
  • cell survival curve
    ¼¼Æ÷»ýÁ¸°î¼±
  • combat survival
    ÀüÅõ»ýÁ¸(¡­ßæðí).
  • crude survival rate
    Á¶»ýÁ¸À²
  • cumulative survival rate
    ´©Àû»ýÁ¸À²
  • desert survival
    »ç¸·»ýÁ¸(Ë×ËÎË×Ì¡).
  • disease free survival
    ¹«º´»ýÁ¸
  • erythrocyte survival
    ÀûÇ÷±¸»ýÁ¸
  • five year survival rate
    5³â»ýÁ¸À².
  • jungle survival
    Á¤±Û»ýÁ¸(¡­ßæðí).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half-reaction time
    ¹Ý¹ÝÀÀ ½Ã°£(ÚâÚãëëãÁÊà)
  • half-time
    ¹Ý ½Ã°£(ÚâãÁÊà)
  • exponential survival curve
    Áö¼ö »ýÁ¸ °î¼± (ò¦â¦ßæðíÍØàÊ)
  • survival curve
    »ýÁ¸°î¼± (ßæðíÍØàÊ)
  • biological half-life
    »ý¹°ÇÐÀû ¹Ý°¨±â(ßæÚªùÊîÜÚâÊõÑ¢)
  • effective half-life
    À¯È¿ ¹Ý°¨±â(êóüùÚâÊõÑ¢)
  • half-band width
    ¹Ý¶ì ³Êºñ
  • half-cell
    ¹Ý½Ç(Úâãø)
  • half-life
    ¹Ý°¨±â(ÚâÊõÑ¢)
  • half-of-the-sites reactivity
    ¹Ý(Úâ)ÀÚ¸® ¹ÝÀÀ¼º (Úãëëàõ)
  • half-period
    ¹Ý±â°£(ÚâÑ¢Êà)
  • half-reaction
    ¹Ý¹ÝÀÀ(ÚâÚãëë)
  • half-site editing
    ¹Ý(Úâ)ÀÚ¸® ÆíÁý(øºòþ)
  • half-thickness
    ¹Ý°¨(ÚâÊõ) µÎ²²
  • half-value dose
    ¹Ý(Úâ)°ª ¼±·®(àÊÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • half-life; half-time
    ¹Ý°¨±â
  • mean survival time
    Æò±Õ»ýÁ¸½Ã°£
  • survival
    »ýÁ¸
  • biological half life
    »ý¹°ÇÐÀû¹Ý°¨±â
  • effective half life
    À¯È¿¹Ý°¨±â
  • elimination half-life
    ¼Ò½Ç¹Ý°¨±â
  • half Fourier imaging
    ¹ÝFourier¿µ»ó
  • half lethal dose
    ¹ÝÄ¡»ç·®
  • physical half-life
    ¹°¸®Àû ¹Ý°¨±â
  • acquisition time
    ȹµæ½Ã°£
  • arm to lung time test
    ÆÈÆó¼øÈ¯½Ã°£½ÃÇè
  • correlation time
    »ó°ü½Ã°£
  • data acquisition time
    ÀÚ·áȹµæ½Ã°£
  • delay time
    Áö¿¬½Ã°£
  • diffusion time
    È®»ê½Ã°£
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
ST esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor...
PST pancreatic suppression test; paroxysmal supraventricular tachycardia; penicillin, streptomycin, and ...
CT calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ...
PTT partial thromboplastin time; particle transport time; posterior tibial tendon (transfer); prothrombi...
CSR central supply room; chart-stimulated recall [test]; Cheyne-Stokes respiration; continued stay revie...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HRT Half-relaxation time
T 1/2 Half-time
PHT Pressure Half Time
t 1/2 The half time
1/2 RT half-relaxation time
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cell survival curve
    ¼¼Æ÷ »ýÁ¸ °î¼±
  • jungle survival
    Á¤±Û »ýÁ¸
  • survival
    »ýÁ¸
  • survival rate
    »ýÁ¸À²
  • antibody half-life
    Ç×ü ¹Ý°¨±â
    Ç×ü ºÐÀÚ°¡ Çü¼ºµÈ ÈÄ Æò±Õ »ýÁ¸ÇÏ´Â ½Ã°£À» ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î¼­, º¸Åë µ¿¹°Ã¼³»¿¡¼­ ÀÏÁ¤·®ÀÇ ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 50%¸¦ Á¦°ÅÇÏ´Â µ¥ °É¸®´Â ½Ã°£À¸·Î Ç¥½ÃÇÑ´Ù. ÀÌ ¹Ý°¨±â´Â ¸é¿ª ±Û·ÎºÒ¸°ÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù.
  • elimination half-life
    ¼Ò½Ç ¹Ý°¨±â
  • half asleep
    °¡¸é, ¹Ý¼ö¸é
    ¹ÝÀº Àáµé°í ¹ÝÀº ÀáµéÁö ¾ÊÀº »óÅÂ.
  • half impaction of the tooth
    ¹Ý ¸Åº¹Ä¡
    Ä¡¾Æ°¡ ¿ÏÀüÈ÷ ¸ÍÃâµÇÁö ¾Ê°í ¹Ý¸¸ ¸ÍÃâµÇ°í ¹ÝÀº °ñ³»¿¡ ¸Åº¹µÇ¾î ÀÖ´Â Ä¡¾Æ.
  • half round tube
    ¹Ý¿ø °ü
  • half spherical cavity
    ¹Ý±¸Çü ¿Íµ¿
  • half the number
    ¹Ý¼ö
  • half vision
    Çü»ó ½Ã
  • half way house
    Áß°£ÂëÀÇ ÁÖ°Åó, Áß°£ Á¡
    Á¤½Å°ú ȯÀÚ, ¾à¹° Áßµ¶ÀÚ, ¾ËÄÝ Áßµ¶ÀÚ °°Àº ȯÀÚµé Áß ¿ÏÀü ÀÔ¿øÀº ÇÊ¿äÄ¡ ¾ÊÀ¸³ª ±×µéÀÌ °øµ¿ »çȸ¿¡ ´Ù½Ã Á¤ÂøµÇ±â±îÁö ÁߵÀÇ °£È£°¡ ÇÊ¿äÇÑ È¯ÀÚµéÀÇ °ÅÁÖó.
  • half-life of immunoglobulin
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ ¹Ý°¨±â
  • lower half headache
    ¾È¸é ÇϹݺΠµÎÅë, ÇϹݺΠµÎÅë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
survival time The period elapsing between the completion or institution of any procedure and death, the life-span of biologically or physically marked erythrocytes or other cells.
(05 Mar 2000)
half and half nail Division of the nail by a transverse line into a proximal dull white part and a distal pink or brown part; seen in uraemia.
(05 Mar 2000)
half-time The time, in a first-order chemical (or enzymic) reaction, for half of the substance (substrate) to be converted or to disappear.
Compare: half-life.
(05 Mar 2000)
median survival <statistics> Median means the middle value. An equal number of people live longer as die earlier than the median.
(16 Dec 1997)
cell survival The span of viability of a cell characterised by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
(12 Dec 1998)
graft survival <haematology> The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
(12 Dec 1998)
survival 1. A living or continuing longer than, or beyond the existence of, another person, thing, or event; an outliving.
2. Any habit, usage, or belief, remaining from ancient times, the origin of which is often unknown, or imperfectly known. "The close bearing of the doctrine of survival on the study of manners and customs." (Tylor) Survival of the fittest.
<biology> See Natural selection, under Natural.
Origin: From Survive.
Source: Websters Dictionary
(01 Mar 1998)
survival analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
(12 Dec 1998)
survival rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
(12 Dec 1998)
disease-free survival Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
(12 Dec 1998)
tissue survival The span of viability of a tissue or an organ.
(12 Dec 1998)
five year survival rate The proportion of patients still alive five years after a diagnosis or form of treatment is completed. Usually applied to statistics of survival of cancer patients, since after five years, recurrences are much less likely to occur.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
long-term survival <oncology> Term used to describe the survival of leukaemia patients who have been disease free for prolonged periods of time, usually at least five years. The chance of disease returning (relapse) decreases with time.
(13 Nov 1997)
biological half-life <biochemistry, biology> This is the time required for one-half of the total amount of a particular substance in a biological system to be consumed or broken down by biological processes when the rate of removal is approximately exponential.
Toxic chemicals with a long biological half-life (such as some pesticides) will tend to accumulate in the body and are, therefore, more likely to be harmful. A substance with a short biological half-life may still accumulate if a portion of it it becomes tightly bound to bone or other tissues, even if most of it is quickly cleared from the body.
(21 Mar 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • survival
    »ì¾Æ ³²À½
  • survival
    ÀÜÁ¸;»ì¾Æ³²À½;»ýÁ¸ÀÚ;ÀÜÁ¸¹°;¿¹ºÎÅÍÀÇ Ç³½À(½Å¾Ó)
  • half time
    ¹ÝÀÏ ±Ù¹«;¹ÝÀϱÞ;(½ºÆ÷Ã÷)ÇÏÇÁ ŸÀÓ;Áß°£ ÈÞ½Ä
  • half time
    ¹ÝÀÏ ³ëµ¿;¹ÝÀϱÞ;Áß°£ ÈÞ½Ä
  • about half way
    Áß°£Âë¿¡
  • half
    Àý¹Ý,Àý¹ÝÀÇ,Àý¹ÝÂë
  • half life
    ¹Ý°¨±â
  • half-seas-over
    ¾ó±ÙÈ÷ ÃëÇÑ
  • center half(back)
    (Ã౸.ÇÏŰ µîÀÇ)¼¾ÅÍ ÇÏÇÁ
  • first half
    »ó¹Ý±â;Àü¹Ý±â;Àü¹Ý;Àü±â
  • half
    (Àý)¹Ý(ÀÇ);ºÒÃæºÐÇÑ;¾îÁö°£È÷;°ÅÀÇ;I ~ wish ...ÇÏ°í ½ÍÀº µíÇÑ »ý°¢µµ
  • half
    (Àý)¹Ý;Áß°£;Áßµµ;and a ~ Ưº°ÇÑ;¾ÆÁÖ ÈǸ¢ÇÑ;by ~ ¹ÝÂë;´ë´ÜÈ÷
  • half andhalf
    ¹Ý¹Ý¾¿ÀÇ(°Í);À̵µÀúµµ ¾Æ´Ñ;¾óÄ¡±âÀÇ;(¹é,ÈæÀÎÀÇ)Æ®±â;¹Ý¹ÝÀ¸·Î
  • half binding
    (Ã¥ÀÇ µî°ú ¸ð¼­¸®¸¸ °¡Á×ÀÎ ¹Ý°¡Á× ÀåÁ¤
  • half blood
    À̺¹,¹è(´Ù¸¥)°ü°è
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á